Bethesda, MD (PRWEB) March 10, 2015
The 18th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases
(NFID), will feature a special closing session at 3:00 PM ET on April
15, 2015 to discuss worldwide collaborative efforts to accelerate
development, clinical trials and the regulatory approval process for
Ebola vaccines.
The West African Ebola virus disease epidemic has alerted the world
to the catastrophic impact that infectious diseases can have. The lack
of preparedness and available vaccines and drugs to prevent and treat
Ebola emphasize the need for a global public-private partnership between
industry, government and non-governmental organizations (NGOs) to best
solve global health crises.
"Updates on Ebola Vaccines in Development," co-sponsored by NFID and the Biotechnology Industry Organization (BIO), will include the following panelists:
• Ripley Ballou, MD, Head of Ebola Vaccine Research, GlaxoSmithKline
• Ripley Ballou, MD, Head of Ebola Vaccine Research, GlaxoSmithKline
• Mark Feinberg, MD, Vice President and Chief Public Health and Science Officer, Merck Vaccines
• Greg Glenn, MD, Senior Vice President Research and Development, Novavax
• Marion Gruber, PhD, Director, Office of Vaccines, U.S. Food and Drug Administration (FDA)
• Michael G. Kurilla, MD, PhD, Director, Office of BioDefense, Research Resources, and Translational Research, NIAID, National Institutes of Health (NIH)
• Hanneke Schuitemaker, PhD, Senior Vice President, Viral Vaccine Discovery, Johnson & Johnson
Panelists will discuss efforts to accelerate development of an Ebola
vaccine, as well as the most significant scientific and clinical
successes and barriers, lessons learned from past and present extreme
health events and the organizations (national and international) that
are instrumental to accelerating development during a public health
emergency.
For additional information about the 18th Annual Conference on Vaccine Research, visit http://www.nfid.org/acvr. Credentialed members of the media should contact Ellyn Terry at eterry(at)nfid(dot)org to register.
About NFID
The National Foundation for Infectious Diseases (NFID) is a non-profit, 501(c)(3) organization founded in 1973 dedicated to educating the public and healthcare professionals about the causes, treatment, and prevention of infectious diseases across the lifespan.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.
Read the full story at http://www.prweb.com/releases/NFID/Ebola/prweb12571066.htm
SOURCE